Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | DNM1 | Q05193 | 7/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11661753 | 1.00 | TSHR (0.53) | TSHRTHRBALDH1A1DNM1LMNA | |
| SCHEMBL6107195 | 1.00 | TSHR (0.53) | TSHRTHRBALDH1A1DNM1LMNA | |
| SCHEMBL119677 | 1.00 | TSHR (0.53) | TSHRTHRBALDH1A1DNM1LMNA | |
| SCHEMBL11690578 | 1.00 | TSHR (0.53) | TSHRTHRBALDH1A1DNM1LMNA | |
| SCHEMBL3277853 | 1.00 | TSHR (0.53) | TSHRTHRBALDH1A1DNM1LMNA | |
| SCHEMBL10318693 | 1.00 | TSHR (0.53) | TSHRTHRBALDH1A1DNM1LMNA | |
| SCHEMBL699509 | 1.00 | — | — | |
| SCHEMBL8447776 | 1.00 | TSHR (0.53) | TSHRTHRBALDH1A1DNM1LMNA | |
| SCHEMBL146783 | 1.00 | — | — | |
| SCHEMBL31181884 | 1.00 | TSHR (0.53) | TSHRTHRBALDH1A1DNM1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025242747-A1 | MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | WO | claimed |
| CN-100548950-C | Process for preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS INC (US) | 2009-10-14 | — | — | CN | claimed |
| US-7273948-B2 | Process of preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS, INC. (US) | 2007-09-25 | — | — | US | claimed |
| EP-1594824-A4 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | ATHEROGENICS INC (US) | 2007-04-04 | — | — | EP | claimed |
| CN-1759084-A | Process for preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS INC (US) | 2006-04-12 | — | — | CN | claimed |
| EP-1594824-A2 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | Atherogenics, Inc. (US) | 2005-11-16 | — | — | EP | claimed |
| US-20040204485-A1 | Process of preparing esters and ethers of probucol and derivatives thereof | CRABTREE ACQUISITION CO, LLC | 2004-10-14 | — | — | US | claimed |
| WO-2004062622-A2 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | ATHEROGENICS, INC. (US) | 2004-07-29 | — | — | WO | claimed |
| EP-4688736-A1 | IMPROVED PROCESS FOR THE PRODUCTION OF AN ASTAXANTHIN INTERMEDIATE | DSM IP Assets B.V. (NL) | 2026-02-11 | — | — | EP | disclosed |
| WO-2025242747-A1 | MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | WO | disclosed |
| WO-2024200695-A1 | IMPROVED PROCESS FOR THE PRODUCTION OF AN ASTAXANTHIN INTERMEDIATE | DSM IP ASSETS B.V. (NL) | 2024-10-03 | — | — | WO | disclosed |
| CN-116925071-A | Preparation method of paliperidone palmitate photodegradation impurity | 丽珠医药集团股份有限公司 | 2023-10-24 | — | — | CN | disclosed |
| US-11633365-B2 | Nucleic acid-containing lipid nanoparticle | KYOWA KIRIN CO., LTD. (JP) | 2023-04-25 | — | — | US | disclosed |
| US-11298326-B2 | Nucleic acid-containing lipid nanoparticles | KYOWA KIRIN CO., LTD. (JP) | 2022-04-12 | — | — | US | disclosed |
| CN-1759084-A | Process for preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS INC (US) | 2006-04-12 | — | — | CN | disclosed |
| EP-1594824-A2 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | Atherogenics, Inc. (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20040204485-A1 | Process of preparing esters and ethers of probucol and derivatives thereof | CRABTREE ACQUISITION CO, LLC | 2004-10-14 | — | — | US | disclosed |
| WO-2004062622-A2 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | ATHEROGENICS, INC. (US) | 2004-07-29 | — | — | WO | disclosed |
| US-6153322-A | Methods for making fluorinated surface modifying agents, methods of using same and products made using same | HOUSTON, UNIVERSITY OF | 2000-11-28 | — | — | US | disclosed |
| US-5587494-A | Practical, cost-efficient chiral synthesis of dihydrosphingosines | THE BOARD OF GOVERNORS FOR HIGHER EDUCATION, STATE OF RHODE ISLAND AND PROVIDENCE PLANTATIONS (US) | 1996-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11633365-B2 | Nucleic acid-containing lipid nanoparticle | LIPA, LIPC, PNLIP | TSHR 3238/4885THRB 3839/4885ALDH1A1 354/4885 |
| US-11298326-B2 | Nucleic acid-containing lipid nanoparticles | FASN, ABHD16A, PHAX | TSHR 3172/4885THRB 3995/4885ALDH1A1 1907/4885 |
| US-20040204485-A1 | Process of preparing esters and ethers of probucol and derivatives thereof | NR3C2, MGLL, GCG | TSHR 1000/4885THRB 269/4885ALDH1A1 2574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.